Manuela Mastronardi

Dr. Manuela Mastronardi

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in Anaesthesia
Verified
Journal Article
Open access
PDF file
Teresa PerraTeresa Perra
Teresa Perra
MMManuela Mastronardi
Manuela Mastronardi
Summary: SARS‐CoV‐2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri‐operative or prior SARS‐CoV‐2 were at further increased risk of venous thromboembolism. We conducted a planned sub‐study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 days of surgery. SARS‐CoV‐2 diagnosis was defined as peri‐operative (7 days before to 30 days after surgery); recent (1–6 weeks before surgery); previous (≥7 weeks before surgery); or none. Information on prophylaxis regimens or pre‐operative anti‐coagulation for baseline comorbidities was not available. Postoperative venous thromboembolism rate was 0.5% (666/123,591) in patients without SARS‐CoV‐2; 2.2% (50/2317) in patients with peri‐operative SARS‐CoV‐2; 1.6% (15/953) in patients with recent SARS‐CoV‐2; and 1.0% (11/1148) in patients with previous SARS‐CoV‐2. After adjustment for confounding factors, patients with peri‐operative (adjusted odds ratio 1.5 (95%CI 1.1–2.0)) and recent SARS‐CoV‐2 (1.9 (95%CI 1.2–3.3)) remained at higher risk of venous thromboembolism, with a borderline finding in previous SARS‐CoV‐2 (1.7 (95%CI 0.9–3.0)). Overall, venous thromboembolism was independently associated with 30‐day mortality (5.4 (95%CI 4.3–6.7)). In patients with SARS‐CoV‐2, mortality without venous thromboembolism was 7.4% (319/4342) and with venous thromboembolism was 40.8% (31/76). Patients undergoing surgery with peri‐operative or recent SARS‐CoV‐2 appear to be at increased risk of postoperative venous thromboembolism compared with patients with no history of SARS‐CoV‐2 infection. Optimal venous thromboembolism prophylaxis and treatment are unknown in this cohort of patients, and these data should be interpreted accordingly.

17 May 2020 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
GVGiuseppe Vizzielli
Giuseppe Vizzielli
FCFrancesco Cosentino
Francesco Cosentino
Diego RaimondoDiego Raimondo
Diego Raimondo
LTLuigi C. Turco
Luigi C. Turco
VVVirginia Vargiu
Virginia Vargiu
RSRenato Seracchioli
Renato Seracchioli

1 January 2021 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
DRDiego Raimondo
Diego Raimondo
GBGiulia Borghese
Giulia Borghese
MMMohamed Mabrouk
Mohamed Mabrouk
AAAlessandro Arena
Alessandro Arena
MAMarco Ambrosio
Marco Ambrosio
RSRenato Seracchioli
Renato Seracchioli

1 January 2020 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
MMMohamed Mabrouk
Mohamed Mabrouk
Diego RaimondoDiego Raimondo
Diego Raimondo
MMManuela Mastronardi
Manuela Mastronardi
IRIvano Raimondo
Ivano Raimondo
SFSimona Del Forno
Simona Del Forno
RSRenato Seracchioli
Renato Seracchioli

17 May 2021 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
Diego RaimondoDiego Raimondo
Diego Raimondo
CACarlo Alboni
Carlo Alboni
BOBenedetta Orsini
Benedetta Orsini
AAAnna Chiara Aru
Anna Chiara Aru
AFAntonino Farulla
Antonino Farulla
RSRenato Seracchioli
Renato Seracchioli
Introduction: Robot‐assisted laparoscopic surgery (RALS) has gained widespread application in several surgical specialties. Previous studies on the feasibility and safety of RALS vs standard laparoscopy (S‐LPS) for rectosigmoid endometriosis are limited and reported conflicting data. This study aims to compare S‐LPS and RALS in patients with rectosigmoid endometriosis in terms of perioperative surgical and clinical data.Material and methods: This is a multicentric, observational, prospective cohort study including 44 patients affected by rectosigmoid endometriosis referred to two tertiary referral centers for endometriosis from September 2018 to September 2019. Patients were divided into two groups: 22 patients underwent S‐LPS, and 22 underwent RALS. Our primary outcome was to compare operative time (from skin incision to suture) between the two groups. Secondary outcomes included: operative room time (patient entry into operative room and patient out), estimated blood loss, laparotomic conversion rate, length of hospital stay, perioperative complications, and evaluation of endometriosis‐related symptoms at 12‐month follow up.Results: The two groups were comparable regarding preoperative and surgical data, except for higher rates of hysterectomies and bilateral uterosacral ligament removal procedures in the RALS group. Also after adjusting for these discrepancies, operative time was similar between S‐LPS and RALS. Operative room time was statistically longer in the RALS group compared with that of S‐LPS. No statistically significant difference was found concerning other study outcomes. Pain and bowel symptoms improved in both groups at 12‐month follow up.Conclusions: If performed by expert teams, RALS provides similar perioperative outcomes compared with S‐LPS in rectosigmoid endometriosis surgical treatment, except for longer operative room time.

16 July 2022 in Pancreatology
Verified
Journal Article
Closed access
MPMauro Podda
Mauro Podda
DPDaniela Pacella
Daniela Pacella
GPGianluca Pellino
Gianluca Pellino
FCFederico Coccolini
Federico Coccolini
AGAlessio Giordano
Alessio Giordano
AMAbdullah Meead
Abdullah Meead